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ABSTRACT
Prostate cancer cells commonly spread through the circulation, but few successfully generate metastatic foci in bone. Osteoclastic
cellular activity has been proposed as an initiating event for skeletal metastasis. Megakaryocytes (MKs) inhibit osteoclastogenesis, which
could have an impact on tumor establishment in bone. Given the location of mature MKs at vascular sinusoids, they may be the first cells
to physically encounter cancer cells as they enter the bone marrow. Identification of the interaction between MKs and prostate cancer
cells was the focus of this study. K562 (human MK precursors) and primary MKs derived from mouse bone marrow hematopoietic
precursor cells potently suppressed prostate carcinoma PC-3 cells in coculture. The inhibitory effects were specific to prostate carcinoma
cells and were enhanced by direct cell-cell contact. Flow cytometry for propidium iodide (PI) and annexin V supported a proapoptotic
role for K562 cells in limiting PC-3 cells. Gene expression analysis revealed reduced mRNA levels for cyclin D1, whereas mRNA levels of
apoptosis-associated specklike protein containing a CARD (ASC) and death-associated protein kinase 1 (DAPK1) were increased in PC-3
cells after coculture with K562 cells. Recombinant thrombopoietin (TPO) was used to expand MKs in the marrow and resulted in
decreased skeletal lesion development after intracardiac tumor inoculation. These novel findings suggest a potent inhibitory role of MKs
in prostate carcinoma cell growth in vitro and in vivo. This new finding, of an interaction of metastatic tumors and hematopoietic cells
during tumor colonization in bone, ultimately will lead to improved therapeutic interventions for prostate cancer patients.  2011
American Society for Bone and Mineral Research.
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Introduction
P
rostate cancer is the most common malignancy in American
men. It alone accounts for about 25% of cancer cases in
men.
(1) Bone metastasis is the major cause of mortality
associated with prostate cancer and affects up to 90% of
patients dying with advanced disease.
(2) The classic concept that
circulating tumor cells need ‘‘congenial soil’’ to ‘‘seed’’ has
stimulated attention focused on understanding the dynamic
migratory abilities of tumor cells.
(3) Meanwhile, understanding
the characteristics and early changes occurring in the bone
marrow microenvironment that welcome incoming cancer cells
is still lacking. Within the skeleton, prostate cancer often spreads
to the axial skeleton and long bone metaphyses, sites under
activeremodelingthatcontainrobustmarrowcellularity.
(4)Bone,
as a dynamic and complicated system, is filled with rich bone
marrow and blood vessels. There are two kinds of stem cells that
reside in the bone marrow: hematopoietic stem cells (HSCs) and
mesenchymal stem cells (MSCs). HSCs and their progeny are
surrounded by stromal cells in the marrow. MSCs reside in the
bone and give rise to the majority of marrow stromal cell
lineages, including chondrocytes, osteoblasts, fibroblasts, adi-
pocytes, endothelial cells, and myocytes.
(5,6) Developing hema-
topoietic cells in the bone marrow are retained until they mature
and are released into the circulation. That hematopoietic cells
have been observed in close juxtaposition to osteoblasts (OBs)
and that cytokines known to be important for hematopoiesis are
expressed on the cell surfaces or secreted by OBs have lead
scientists to explore the interaction between hematopoietic
cells and cells of the marrow stromal cell lineage. Increased
observations show that the osteoblastic niche is important in
supporting and maintaining HSCs.
(7) Megakaryocytopoiesis
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125occurs in the hematopoietic (extravascular) compartment of
the marrow; megakaryocytes (MKs) then migrate and locate
parasinusoidally, the cytoplasm invaginates, penetrates the
endothelial cell lining, and platelets are released into the blood
circulation.
(8) This process isregulated by the actionof numerous
factors, including cytokines, growth factors, chemokines, and
extracellular matrix molecules (ECMs), many of which are pro-
duced by stromal cells within the marrow microenvironment.
The development and proliferation of osteoblasts directly
influences hematopoiesis
(7,9–11) and megakaryopoiesis,
(12,13)
further illustrating the significance of these interactions.
Recently, MKs have been demonstrated to have inhibitory
effects on osteoclast (OC) formation and activity.
(14–17) These
studies demonstrated that a factor or factors secreted by MKs
inhibit OC development. The emerging paradigm is that MKs
play a dual role in regulating skeletal homeostasis by simu-
ltaneously stimulating OB proliferation and differentiation and
inhibiting OC development.
(14–17) As a result, alterations in MK
proliferation or differentiation also could affect skeletal changes.
Considering that boneresorption isfavorable totumor growth in
bone
(18–20) and there is a high tendency of prostate cancer to
localize in bone, MKs may indirectly inhibit tumor growth via
decreased OC resorption and reduced cytokine and growth
factor release from the bone matrix.
(15–17) Another possibility is
that MKs directly affect prostate cancer cells in their trajectory
through the bone marrow microenvironment. However, inves-
tigations on the interaction between MKs and metastatic tumor
cells are minimal. This study is based on the hypothesis that MKs
inhibit prostate cancer cell growth in bone through direct
inhibition of cancer cells and indirectly by their influence in the
bone microenvironment.
Materials and Methods
Cell culture
Human hematopoietic precursor cells K562 (a patient-derived
leukemiacell lineexpressing botherythroid andMKmarkers that
can be induced to differentiate along each of these pathways)
and Meg01 (a patient-derived megakaryoblastic cell line) were
used as precursors for MKs. HL60 cells (a patient-derived
promyelocytic leukemia cell line that can be differentiated to
neutrophilic promyelocytes) were cultured in suspension under
appropriate growth conditions. K562 cells were maintained in
Iscove’s Modified Dulbecco’s Media (IMDM)þ10% fetal bovine
serum (FBS) (Invitrogen Corp., Carlsbad, CA, USA) and induced
with 50nM of phorbol myristate acetate (PMA) (Sigma Chemical
Co., St. Louis, MO, USA) to differentiate into mature MKs. To
differentiate K562 cells to erythroid cells, 40nM of doxorubicin
hydrochloride (DOX, Sigma) was added to the culture medium of
K562cellsfor3days.Meg01cellsandHL60cellsweremaintained
inRPMI(RoswellParkMemorialInstitute)1640mediaþFBS.Both
cells were passaged at a density of about 2 10
5/mL when
seeding.
Primary MKs were isolated and cultured from mouse bone
marrow cells. Briefly, after flushing and centrifugation with Ficoll-
Paque (GE Healthcare, Piscataway, NJ, USA), bone marrow cells
were harvested, counted, and seeded at 10
6/mL with addition of
nucleotide mixtures (Invitrogen), thrombopoietin (TPO), inter-
leukin 6 (IL-6), and IL-11 (PeproTech, Rocky Hill, NJ, USA). Five or
six days later, MKs were enriched by gravity sedimentation twice
before use for coculture assay. The upper-portion cells were
collected as less mature MKs and the bottom-layer cells
were collected as mature MKs. The primary MK culture method
was the same as described previously, where it was demon-
strated that after 6 days of culture, the purity of MKs (both in
medium-sized and large populations) was 98%.
(21)
PC-3 prostate carcinoma cells stably expressing luciferase (PC-
3
Lucþ, referred to as PC-3)
(22) and C4-2b cells were maintained in
RPMI 1640þ10% FBS. The VCaP prostate carcinoma cell line was
maintained in DMEMþ10% FBS. Cells were passaged using
trypsin with EDTA (Invitrogen) and resuspended in appropriate
growth medium.
Human osteoblastic SaOS2 cells were maintained and
passaged every 4 to 5 days in a-MEM (Invitrogen) containing
100 units/mL of penicillin and streptomycin and 10% FBS. SaOS2
cells were plated at 50,000 cells/cm
2 and cultured to 80% to 90%
confluence.
Viable cell enumeration
Five thousand (5 10
3) cells (adherent prostate carcinoma
cells or osteoblastic cells) were plated per well in 24-well plates
in quadruplicate in the presence of serum at the indicated
concentrations. K562 cells, HL60 cells, or MKs induced from
K562 cells were seeded in the suspension medium over the
adherent cells. On the indicated days, suspension cells were
removed before PC-3 cells were washed and trypsinized.
The luciferase activity of cell lysates as a reflection of cell
number was determined with the dual luciferase reporter assay
system (Promega, Madison, WI, USA) and a Monolight 2010
Luminometer (BD-Pharmingen, San Diego, CA, USA). The non-
luciferase-expressing adherent cells were washed with PBS and
fixed with 40%methanol, followed by staining withcrystal violet.
DNA binding dye was solubilized with 10% acetic acid. Relative
cell numbers were measured by optical density at 595nm.
Protein isolation and analysis
Protein levels of apoptosis-associated specklike protein contain-
ing a CARD (ASC) and death-associated protein kinase 1 (DAPK1)
were determined by Western blot using total cell lysates. Briefly,
cells were washed with cold PBS and collected with Invitrogen
SDS buffer. Samples were stored at  208C until assays were
performed. Western blots were performed using actin as a
loading control in each sample (all antibodies were from Cell
Signaling Technology, Danvers, MA, USA). Western blot films
were scanned, and relative protein expression was quantified
using the ImageJ analysis program.
In vivo prostate cancer models
Four-week-old male athymic mice were obtained from Harlan
(Indianapolis, IN, USA). Mice (20/group) were pretreated with
TPO or vehicle for 5 days before inoculation of tumor cells. Five
mice from each group were euthanized for histology and flow
cytometry analyses using fluorescein isothiocyanate (FITC)–
labeled CD41 antibody (BD-Pharmingen) to determine CD41
þ
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The remaining mice were sedated with 1.7% isoflurane mixed
with air, and 100,000 PC-3 cells were inoculated via intracardiac
injection into the left ventricle, as described previously.
(23) Mice
were sacrificed after 4 weeks, and the skeletons were exposed to
X-ray film (Wolverine X-Ray, Dearborn, MI, USA) at 32kV for
45seconds in a microradiography X-ray machine (Faxitron,
Madison, WI, USA) to identify gross skeletal changes. Tibias were
fixed in 10% formalin, decalcified, and processed for histologic
analysis. All animal studies were approved by the University of
Michigan Committee on the Use and Care of Animals (UCUCA).
In vivo localization and growth of PC-3 prostate
cancer cells
In vivo bioluminescent imaging was carried out at the University
of Michigan Small Animal Imaging Resource facility. Before
imaging, mice were injected i.p. with 100mL of 40mg/mL
luciferin dissolved in PBS. Imaging was performed under 1.75%
isoflurane/air anesthesia on a cryogenically cooled in vivo
imaging system (IVIS) equipped with a 50-mm lens and coupled
with a data-acquisition PC running Living Image Software 2.6
(Xenogen Corp., Alameda, CA, USA). Ventral images were
acquired 12minutes after injection. Pseudocolor images of
photon emissions were overlaid on grayscale images of mice to
aid in determining signal spatial distribution. Photon quantifica-
tions were calculated within regions of interest (ROI).
Histology and immunohistochemistry
Xenograft tumors were harvested and placed in fresh 10%
formalin. Tibias were decalcified in 10% EDTA for 21 days prior to
paraffin embedding. Paraffin-embedded specimens were sec-
tioned (5mm) and stained with either hematoxylin and eosin
(H&E), trichrome (bone), or tartate resistant acid phosphatase
(TRACP) (osteoclasts; Acid Phosphatase, Leukocyte Kit, Sigma), or
immunohistochemistry was performed for von Willebrand factor
(vWF). Standard indirect immunoperoxidase procedures were
used for immunohistochemistry using the AEC Cell and Tissue
Staining System (R&D Systems, Minneapolis, MN, USA). Mayer’s
hematoxylin (Sigma) was used for counterstaining.
Flow cytometric analysis for cell cycle and apoptosis
Cells were washed twice with cold PBS and lifted with trypsin for
3minutes at 378C before being stained with propidium iodide
(PI) or the Annexin V-FITC Apoptosis Detection System (BD-
Pharmingen). Cells also were treated with ribonuclease A before
staining with PI for cell cycle analysis. FITC-conjugated annexin
V and PI staining were evaluated with a FACs Calibur (BD
Bioscience, San Jose, CA, USA).
RNA isolation and mRNA quantification
RNA was isolated using Tri reagent (Sigma) following the
manufacturer’s protocols. One microgram of total RNA was
reverse transcribed in a 20-mL reaction volume containing
random hexamers using a reverse-transcription assay system
(Applied Biosystems, Foster City, CA, USA). Semiquantitative RT-
PCR was performed on a GeneAmp 7700 thermocyler (Applied
Biosystems), and fold changes were determined via the DDCT
method with normalization to GAPDH mRNA levels.
Statistical analysis
One-way ANOVA or the Student’s t test for independent analysis
was applied to evaluate differences, and Fisher’s exact test was
applied to compare the incidence rate of lesion development
using the GraphPad Instat Software Program (GraphPad Soft-
ware, Inc., San Diego, CA, USA). A value of p<.05 was considered
statistically significant. All assays were repeated a minimum of
two times with similar results.
Results
K562/MK cells inhibited prostate carcinoma cell growth
in vitro
The K562 cell line is an established precursor cell line of MKs
and erythroid cells on differential stimulation. When induced
by PMA, K562 cells differentiate into MKs accompanied by a net
increase in megakaryocytic markers and a reduction in erythroid
markers.
(24) K562 cells, with or without PMA pretreatment, were
cocultured with the prostate carcinoma cell line PC-3 previously
labeled with a luciferase tag. Strong inhibition of PC-3 growth
was found in both conditions (Fig. 1A). This inhibitory effect of
K562 on prostate carcinoma growth was further confirmed using
two other prostate carcinoma cell lines, VCaP and C4-2B cells
(Fig. 1B, C). In addition, primary MKs derived from mouse bone
marrow also cells demonstrated significant inhibition of PC-3 cell
growth in coculture (Fig. 1D). The primary megakaryocytes used
in coculture were fairly pure (>90%) after gravity sedimentation,
as measured by flow cytometry using CD41 as the marker for MK
(Supplemental Fig. 1).
K562/MK inhibition of cell growth is specific to
prostate carcinoma and enhanced by close proximity
Toexamine the specificityof MKinhibition ofprostate carcinoma
cell growth, cocultures with nonepithelial SaOS2 cells, a human
osteosarcoma cell line, and HL60, a human promyelocytic
leukemia cell line, were performed. Unlike the inhibitory effects
seen with prostate carcinoma cells, a significant stimulation of
SaOS2 cell growth was observed (Fig. 2A). Furthermore, HL60
failed to regulate the growth of prostate carcinoma (Fig. 2B). To
evaluate the dependence of direct cell-cell contact on the
inhibitory effects of prekaryocytes and MKs, a transwell culture
system was used, in which PC-3 cells and K562 cells or MKs were
cultured separately in the upper and lower wells, respectively.
The inhibitory effect of MKs on PC-3 cells was still present but
was significantly blunted when K562 cells or MKs differentiated
from K562 cells (MK-K562 cells) were cultured with PC-3 cells in
the transwell system without direct contact (Fig. 2C). Without
very close proximity or cell-cell contact, K562 cells still blocked
the growth of PC-3 cells by 35% (transwell plate), whereas
mature MKs only inhibited PC-3 cell growth by 15% in transwell
plates versus 55% in regular-well coculture. This suggests that a
very close proximity or direct cell-cell contact isimportant for the
maximal inhibitory effects of mature MKs. Thus either a very
steep inhibitory cytokine/growth factor gradient that requires
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requires direct cell-cell contact to exert the inhibitory effects
exists.
Primary megakaryocytes inhibited PC-3 cell growth
regardless of maturation phase
Since the inhibitory effect of K562 cells was more potent than
that of mature MKs derived from K562 cells, primary MKs cultur-
ed from mouse bone marrow were used to determine whether
maturation of MKs affects their inhibitory ability. Primary MKs at
different mature phases were cultured with PC-3 cells for 3 days.
Both populations suppressed PC-3 cell growth without sig-
nificant differences (Fig. 3A). Erythroid cells derived from K562
cells also were tested for the effects on prostate carcinoma cell
growth in a coculture system (Fig. 3B). Unlike MKs derived from
K562 cells, erythroid cells differentiated from K562 cells inhibited
PC-3 cell growth by only 20%. Considering that the 3-day 40nM
of DOX treatment can only partially differentiate K562 cells to
erythroid cells (Supplemental Fig. 2),
(25) it is likely that the 20%
inhibitoryeffectsactuallywereduetotheremainingK562cellsin
the culture, and the influence of erythroid cells was minimal.
K562/MKs induced apoptosis in PC-3 cells
To understand the mechanism ofthe inhibitory effects of MKs on
prostate carcinoma cell growth, the MK and PC-3 coculture
system was evaluated with cell-cycle and apoptosis assays. Flow
cytometric analysis demonstrated that K562 and MK-K562 cells
altered the ratios of PC-3 cells in cell-cycle phases (Supplemental
Fig. 3A). The percentage of cells in G0/G1 phase increased,
whereas cells in S and G2/M phases decreased by coculture with
K562 and MK-K562 cells. It was further demonstrated by
quantitative polymerase chain reaction (qPCR) that there was
a 50% decrease in PC-3 cyclin D1 mRNA levels after 48hours of
coculture with K562 cells (Supplemental Fig. 3B); however, these
changes were not enough to decrease PC-3 cell growth to the
extent observed. K562 cells and another MK precursor cell,
Meg01 cells, also significantly induced apoptosis of PC-3 cells. A
dramatic increase in annexin V
þ cell (early apoptotic cells)
number was observed in PC-3 cells after 24 and 36hours of
coculture withK562cells. Asignificantincreaseinearlyapoptotic
cells was observed in PC-3 cells cultured with Meg01 cells at
48hours (Fig. 4A). This was followed by a significant increase in
both annexin V
þ and PI
þ cell populations (late apoptotic cells) in
PC-3 cells after 48hours of coculture with K562 cells and Meg01
cells (Fig. 4B). An apoptosis pathway analysis (Supplemental
Table 1) revealed ASC and DAPK1 as two highly stimulated genes
in PC-3 cells after coculture with K562 cells. The significant
induction of both ASC and DAPK1 mRNA levels was confirmed
with qPCR (Fig. 4D, E). The protein levels of both ASC and DAPK1
were increased in PC-3 cells after 48hours of incubation with
K562 cells (Fig. 4F–H). Until 72hours, ASC protein levels still were
significantly higher than control.
Increased MKs in vivo were associated with reduced
prostate skeletal metastatic lesions
Thrombopoietin (TPO), the major MK growth factor is required
forMKproliferationandmaturationandwasusedtoexpandMKs
to determine their impact on tumor metastasis in vivo (Fig. 5A).
Fig. 1. Prostate carcinoma cell growth is inhibited by K562/MK cells in vitro. Five thousand luciferase-tagged prostate carcinoma PC-3 cells (PC-3
lucþ,
adherent, referred to as PC-3) were cocultured with 20,000 K562 cells (nonadherent) or mature MKs derived from K562 cells or mouse bone marrow cells
(nonadherent,referred to as MK-K562 cells) for up to 6 days. MK cells were removed with the supernatant, and only adherent cells were analyzed. (A) PC-3
cell lysates were analyzedfor luciferaseactivity using the luciferase assay reagent (Promega).VCaP (B) and C4-2B (C) cells were fixed and stained following
a protocol using crystal violet. (D) Ten thousand PC-3 cells were cocultured with 10,000 mature primary MKs for up to 48hours. PC-3 cell lysates were
analyzed for luciferase activity using the luciferase assay reagent. All assays were performed in triplicate.
 p<.05;
  p<.005 versus PC-3 alone.
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histologicstainingfortheMKmarkervonWillebrandfactor(vWF)
and flow cytometric analysis of CD41
þ cells in the bone marrow
of a subset of athymic mice from each group 1 day after the
last injection of TPO or vehicle (veh) and before cardiac
inoculations (Fig. 5B–D). The incidence of lesion development in
the legs after intracardiac inoculation of PC-3 cells was
significantly reduced in mice pretreated with TPO (Fig. 5E).
Meanwhile, the bioluminescence (BLI) activity of bone lesions in
the legs of TPO-treated mice was less than in the vehicle-treated
group at 2 weeks after tumor cell inoculation (Fig. 5F). Consistent
with these live-image results, histomorphometric analysis
indicated that the tumor area in the tibias of mice pretreated
with TPO at euthanization was significantly less than in the
controls (Fig. 5G–I).
Based on these results, a schematic model was proposed to
summarize the findings (Fig. 6). MKs inhibit prostate cancer cell
growth in bone through direct induction of cancer cell apoptosis
and indirectly, as described by others, by decreasing bone
remodeling.
(16,17)
Fig. 2. MK inhibition of cell growth is specific to prostate carcinoma and
enhanced by close proximity. (A) Growth of PC-3 cells was inhibited,
whereas human osteoblastic cell (SaOS2) growth was upregulated by
K562 cells after 3 days of coculture. (B) K562 cells but not HL60 cells
inhibited the growth of PC-3 cells after 3 days of coculture. K562 and
HL60 cells were removed with supernatant, and only adherent cells were
left for the analysis. (C) Five thousand PC-3 cells were cultured in the
upper chambers with 20,000 K562 cells or MKs differentiated from K562
cells in the bottom wells for 3 days. After three washes with PBS, PC-3 cell
lysates were analyzed immediately for luciferase activity (data shown as
percent change versus luciferase activity of PC-3 cells alone). All assays
were performed in triplicate.
 p<.05;
  p<.005 versus PC-3 or SaOS2
cells alone.
Fig. 3. MKs but not erythroid cells inhibited PC-3 cell growth. (A) Ten
thousand PC-3 cells were cocultured with 10,000 primary mature (larger
sizeCD41
þ)orlessmature(immature,smallersizeCD41
þ)MKsfor3days.
(B) Ten thousand PC-3 cells were cocultured with 10,000 erythroid cells
derived from K562 cells after doxorubicin hydrochloride (DOX) treatment
(40nM).In bothexperiments,PC-3 cellswerewashedtwicewith PBS,and
the cell lysates were collected with passive lysis buffer and analyzed for
luciferase activity and expressed as photons per second. Assays were
performed in triplicate.
 p<.05;
  p<.001 versus PC3 cells alone.
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Meg01 cells for 24, 36, and 48hours before annexin V and propidium iodide staining. (A) Annexin V
þ and (B) both annexin V
þ and PI
þ cell populations in
PC-3 cells after coculture with K562 cells or Meg01 cells. (C) Representative fluorescence-activated cell-sorting (FACS) images of PC-3 cells cultured with or
without K562 cells at 24 and 48 hour. qPCR using Carboxyfluorescein (FAM)-labeled primers for ASC (D) and DAPK1 (E) mRNA levels. (F) Representative
Western blot of ASC and DAPK1 protein detection in PC-3 cells cultured with K562 cells for 48 and 72hours. Quantitative protein levels of ASC (G) and
DAPK1 (H). All assays were performed in triplicate. N.D.¼ nondetectable.
 p<.05;
  p<.001 versus PC-3 alone.
130 Journal of Bone and Mineral Research LI ET AL.Fig. 5. Expansion of MKs in vivo decreased prostate tumor metastatic lesion development. (A) Schematic of experimental design: Mice (20/group) were
treated with recombinant TPO intraperitoneally to increase MKs. One day after the last injection, 5 mice from each group were euthanized, and one tibia
wascollectedfor (B) vWFimmunohistochemistryand(C) representativeimagesofvWFstaining ofthe tibiasectionsfrom vehicle-andTPO-treated groups
before tumor injection. (C) The other hind limb was flushed with PBS for flow cytometric staining of CD41þ MK cells. (E, F) The remaining mice were
injected via the intracardiac route with 200,000 PC-3 cells, and tumor cell location and activity were recorded with weekly bioluminescence (BLI) imaging.
Thelocationandprogress(E)ofinoculatedprostatecarcinomacellsinmicewererecordedwithBLIimagingweekly,andtheincidencerateoftumorinthe
legs ( F) was enumerated weekly and analyzed by Fisher’s exact test (
 p<.05 versus vehicle). (G) Representative images of BLI of tumor development in
hind limbs of vehicle- (VEH) and TPO-treated groups. (H) Histomorphometric analysis of tumor area in the tibias was decreased in mice pretreated with
TPO.(I)RepresentativeradiographsofhindlimbandH&Estainingofthetibialsectionsfromvehicle-andTPO-treatedgroups4weeksaftertumorinjection.
T¼tumor; B¼bone.
 p<.05;
  p<.01 versus VEH.
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Inthis study, K562cellsand MKsderived eitherfrom K562cellsor
mouse bone marrow cells suppressed prostate carcinoma cell
growth, whereas erythroid cells derived from K562 cells and
another leukemia cell line, HL60, which differentiates along the
Fig. 5. (Continued).
Fig. 6. A schematic model to summarize the findings. MKs inhibit
prostate cancer cell growth in bone through direct inhibition of cancer
cells and indirectly by decreasing bone remodeling. The direct inhibition
involves a marginal cell-cycle arrest via reduction in cyclin D1 and
significant stimulation of apoptosis via induction of ASC and DAPK1.
Meanwhile, MKs exert an anabolic effect in bone by stimulating osteo-
blasts and inhibiting osteoclasts.
(16,17)
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results revealed a novel and specific inhibitory effect of MKs
originated from bone marrow hematopoietic progenitor cells on
prostate carcinoma cell growth in vitro and in vivo. To our
knowledge, this is the first report of a specific MK-mediated
inhibition of prostate cancer cell growth and contributes to the
understanding of the interaction among cancer cells and native
cells in the bone microenvironment. In addition, the location of
mature MKs at the parasinusoids may make them the first
defensive cells in the bone marrow facing tumor cells in their
extravascular process.
Bone turnover contributes to tumor localization, and bispho-
sphonates, which suppress bone turnover, have been used
effectively for the management of cancer-induced skeletal
metastasis.
(4,26–28) Since MKs potently inhibit osteoclastogenesis
in vitro,
(16) expansion of MKs with TPO may result in reduced
osteoclast activity in vivo, which also inhibits prostate carcinoma
cell growth in the bone marrow. Hence the decrease in prostate
tumor bone lesion development in mice pretreated with TPO
could be the combined effect of altered OCs (indirect) and MK
cells (direct). However, in this study, the direct effects may be the
major ones because the reduction in OC activity was mild and
not significant after 5 days of TPO treatment (Supplemental
Fig. 4).
The inhibitory effects of MKs on prostate carcinoma were
not sustained over time in vivo because the luciferase activity of
the tumor cells in the hind limbs of the TPO-treated mice caught
up with that of the vehicle-treated mice at 3 weeks after
tumor inoculation. These data may imply that the inhibitory
effects from MKs and their precursors are early events taking
place during tumor cell seeding in the marrow. During this
period, MKs have advantages over the tumor cells in regard to
cell numbers and/or density. Once the tumor cells exit the blood
vessels and enter the marrow, they may be under limited
influence of MKs because there may be less opportunity for their
encounter.
It has been reported that granulocyte colony-stimulating
factor (G-CSF) treatment enhanced bone tumor growth in
mice.
(29) Both G-CSF and TPO may increase bone marrow
cellularity, but since TPO treatment reduced tumor growth and
G-CSF increased tumor growth in bone, this suggests that the
decrease in skeletal tumor burden in TPO-treated mice was less
likely due to the general changes in bone marrow cellularity.
MKs produce platelets, which have been shown to support the
metastatic potential of tumor cells, and inhibiting platelet
aggregation decreases tumor metastasis.
(30,31) It is possible that
with the expansion of MKs in the bone marrow, the number of
platelets increased, which favored tumor growth later and hence
a reduction in tumor protection with time after TPO treatment.
Interestingly, the size ofplatelets isreduced inpatients withsolid
tumors and skeletal metastasis.
(32) Although the mechanism
underlying this observation is obscure, it is known that platelet
size is determined at the MK stage and is inversely proportional
to MK ploidy.
(33) MK ploidy is regulated by cytokines such as IL-3
and IL-6, which contribute to more reactive and larger
platelets.
(33,34) Identifying the interaction between tumor cells
andMKscouldresultinabetterunderstandingofthedecreasein
platelet size in patients with skeletal metastasis.
In mice, PC-3 cells have a tendency to metastasize to the jaw
when they are injected into the circulation. Interestingly, in
contrast to the long bones, tumor development in the jaws was
similar between TPO- and vehicle-treated groups with intra-
cardiac inoculation of PC-3 cells (Supplemental Fig. 5). Compar-
ing the jaw with the long bones, there is a smaller marrow cavity;
thus the structure of the jaw sets a limitation on the marrow
cavity, as well as reduced numbers of MKs. The continuous tooth
eruption of rodents and high bone turnover rates also may
contribute to tumor development in the jaw. Hence the inhi-
bitory effects of MKs in this location may be overruled by other
factors in this model system.
Our data indicated that K562 cells suppressed the growth of
prostate carcinoma cells mainly through enhancing apoptosis.
Further experiments revealed that two apoptotic genes, ASC and
DAPK1, were highly regulated genes associated with the inhi-
bitory effects during coculture. ASC, as indicated by its name,
apoptosis-associated specklike protein containing a CARD,
contains a caspase recruitment domain (CARD), suggesting a
role in caspase-mediated cell death. It has been shown that in
breast cancers, ASC-induced apoptosis proceeds through a
CARD-dependent aggregation step followed by activation of a
caspase-9-mediated pathway.
(35) Interestingly, both ASC and
DAPK1 gene promoters are reported to be hypermethylated in
prostate carcinoma, including the PC-3 cell line.
(36–39) Methyla-
tion inthe promoter often involves loss offunction of a geneand
thus plays an essential role in maintaining normal cell function.
Aberrant DNA methylation patterns may be the earliest somatic
genome changes in prostate cancer. Changes in methylation
contribute to multiple cancer development.
(40,41) This study
revealed a significant increase in ASC and DAPK1 expression in
PC-3 cells after coculture with K562 cells, suggesting that K562
may induce PC-3 cell apoptosis through increasing the
abundance of these genes normally deregulated in the process
of carcinogenesis.
In summary, the original finding of megakaryocytic cell in-
hibitory effects on prostate carcinoma cells unmasked a novel
osteoimmunologic response to the invasion of prostate carci-
noma cells during skeletal metastasis. Moreover, discovery of the
downstream mediators, ASC and DAPK1, provided new potential
therapeutic targets for prostate cancer.
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